Brett Shandler advises life science clients on licensing, intellectual property, regulatory, and corporate matters.
Prior to joining Latham, Mr. Shandler acted in patent litigation and regulatory matters involving pharmaceuticals, biologics, genetic technologies, and medical devices. He also gained experience defending high-value damages claims brought by government health departments.
Mr. Shandler also has experience in technology matters, and has a particular interest in IP and antitrust issues arising in the context of standard essential patents (SEP) and fair, reasonable, and non-discriminatory (FRAND) licensing.
Mr. Shandler has been recognized as a Rising Star by Managing IP.